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S U M M A R Y
Background: The utility of carbapenems, which are considered ‘last-line’ agents, is being diminished by
the growing incidence of various resistance mechanisms in bacteria. We aimed to investigate the
molecular mechanism of carbapenem resistance in Enterobacter cloacae recovered from a 76-year-old
patient who had undergone coronary artery bypass grafting and repair of the mitral and tricuspid valves.
Interestingly, the patient had no prior history of hospital admission abroad.
Methods: The Carba-NP test II and synergy testing were performed to conﬁrm carbapenemase activity.
PCR was used to detect carbapenemase-encoding genes. Nucleotide and amino acid sequence analysis
was performed to identify OXA-48 variants. Moreover, we performed multilocus sequence typing (MLST)
of multidrug-resistant (MDR) E. cloacae.
Results: We detected no signiﬁcant increase in zone diameter around disks with inhibitors. However, the
Carba-NP test II revealed carbapenemase activity in all isolates. All isolates showed the presence of the
exact OXA-48 carbapenemase variant. Furthermore, MLST analysis revealed that the MDR E. cloacae
isolates belonged to ST89.
Conclusions: We report a case of infection caused by a unique carbapenem-resistant E. cloacae ST89
producing OXA-48 carbapenemase. Interestingly, these pathogens developed resistance to other ‘last-
resort’ agents, namely colistin and tigecycline. There is a crucial need for surveillance programs aimed at
screening for carbapenemase-producing Gram-negative bacteria, especially in patients transferred from
high-incidence areas.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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Nowadays, the utility of carbapenems is being diminished by
the growing worldwide incidence of various resistance mecha-
nisms in Gram-negative bacteria. The occurrence of microorgan-
isms resistant to ‘last-line’ agents represents a particularly high
risk in the healthcare setting. To date, novel carbapenemases of the
OXA-48 family have been distributed mainly in Klebsiella
pneumoniae, but they have begun to emerge in another pathogen* Corresponding author. Tel.: +48 85 746 8571; fax: +48 85 746 8571.
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license (http://creativecommons.org/licenses/by-nc-sa/3.0/).prone to exhibiting multiple drug resistance mechanisms,
Enterobacter cloacae.1–7 In the present study we performed clinical
and retrospective molecular investigations of an infection due to
OXA-48 carbapenemase-producing E. cloacae.
2. Case report
A 76-year-old male with coexisting signiﬁcant mitral and
tricuspid valve regurgitation was admitted to the Department of
Cardiac Surgery. The patient had developed coronary artery disease,
hypertension and bradycardia–tachycardia syndrome, and was in
the third stage of chronic kidney disease. Furthermore, the patient
had no history of travel or admission to a hospital abroad.
In August 2012 a combined cardiac operation was performed:
coronary artery bypass grafting and repair of the mitral andciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
Figure 1. Scheme presenting the administration of antimicrobial agents during the patient’s hospitalization compared to the microbiological diagnostics and susceptibility
testing. Colistin: 2  2 MIU administered intravenously (IV) between day 14 and day 27; 3  2 MIU IV administered from day 28. Imipenem: 4  0.5 g administered IV every
6 h from day 27. Tigecycline: initial dose of 100 mg administered IV on day 28, followed by 2  50 mg administered IV. *See Table 1 for resistance patterns of Enterobacter
cloacae 6185 and 6186.
Table 1
Resistance proﬁle of selected OXA-48 carbapenemase-producing Enterobacter
cloacae
6185 6186 7029
Date of specimen collection 24/09/2012 24/09/2012 7/10/2012
Blood Bronchial
aspirate
Bronchial
secretion
Amikacin R 64 R 64 R 64
Gentamicin R 16 R 16 R 16
Tobramycin R 16 R 16 R 16
Piperacillin R 128 R 128 R 128
Piperacillin–tazobactam R 128 R 128 R 128
Aztreonam R 64 R 64 R 64
Cefepime R 64 R 64 R 64
Ceftazidime R 16 R 16 R 16
Imipenem S 2 I 8 I 8
Meropenem I 4 R 16 R 16
Trimethoprim–sulfamethoxazole R 320 R 320 R 320
Ciproﬂoxacin R 4 R 4 R 4
Colistin S 0.5 R 12 R 16
Tigecyclinea R 8a R 4 R 4
R, resistant; I, intermediate; S, susceptible.
a Tigecycline susceptibility testing was performed retrospectively using the Etest
(bioMe´rieux, Marcy l’Etoile, France).
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bypass (CPB). The left internal thoracic artery (LIMA) was anasto-
mosed to the left anterior descending coronary artery (LAD). Mitral
and tricuspid valve plasties were performed with the implantation
of prosthetic rings. During the ﬁrst hour after the procedure the
patient developed heart failure despite pharmacological support.
The patient underwent an urgent second procedure with the use of
CPB. Two saphenous grafts were implanted into the LAD and right
coronary artery (RCA). Intra-aortic balloon counterpulsation (IABP)
was introduced through a right femoral artery access as mechanical
circulatory support. After the operation, the patient was transferred
to the intensive care unit.
After gradual improvement in his general condition and
stabilization of the circulatory system, the patient subsequently
developed a water–electrolyte imbalance with decreased diuresis
and a high creatinine level. Continuous renal replacement therapy
was started 11 days after surgery. His further postoperative course
included physical rehabilitation, enteral and parenteral nutrition,
and intensive drug treatment with respect to antimicrobial
therapy, which is presented in Figure 1.
On postoperative day 38, after another cardiac decompensa-
tion, coagulation disorders, acute renal failure, and multiple organ
dysfunction syndrome, the patient developed cardiac arrest.
Attempts at resuscitation were unsuccessful and the patient died.
Bronchial secretions recovered on days 37 and 38 after surgery
revealed the failure of antimicrobial treatment to eradicate
carbapenem-resistant E. cloacae.
3. Materials and methods
The ﬁrst isolates of carbapenem non-susceptible E. cloacae were
obtained from blood and bronchial secretions on day 24 after
surgery. Further isolates were recovered from urine and subse-
quent samples of blood and bronchial secretions.
Antimicrobial susceptibility testing of all isolates was per-
formed using the VITEK2 system, following the manufacturer’s
guidelines. Resistance patterns of the selected isolates, interpreted
in accordance with the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) criteria, are presented in Table 1.Moreover, we conducted detailed phenotypic and molecular
analysis of the ﬁrst isolates obtained from bronchial aspirate
and blood and the last isolate obtained from bronchial secretions 1
day before the patient’s death.
Synergy testing of carbapenems (meropenem and imipenem)
with beta-lactamase inhibitors and a biochemical carbapenemase
assay (Carba NP test II) were performed, as described previously.8
We performed PCR with the use of primers allowing the
ampliﬁcation of all currently identiﬁed blaOXA-48-like and subse-
quent amino acid sequence analysis.
Multilocus sequence typing (MLST) was used to classify E.
cloacae isolates. The procedure was performed according to the
scheme evaluated by Miyoshi-Akiyama et al.9, and results were
interpreted according to the protocols on the MLST website
(http://pubmlst.org/ecloacae/) developed by Jolley and Maiden10
and sited at the University of Oxford.
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Phenotypic analysis revealed no signiﬁcant increase in zone
diameter around disks with inhibitors, indicating the absence of
metallo-beta-lactamases and K. pneumoniae carbapenemase (KPC).
However, the Carba NP test II conﬁrmed the production of enzyme
with carbapenemase activity.
PCR experiments showed the presence of a resistance gene
belonging to the OXA-48 family. Nucleotide sequencing and
analysis of the amino acid sequence conﬁrmed the exact OXA-48
carbapenemase variant. Moreover, MLST analysis allowed us to
classify all isolates as sequence type 89 (ST89).
5. Discussion
We report the ﬁrst case of infection caused by a unique
carbapenem-resistant E. cloacae ST89 producing OXA-48 carba-
penemase in Central Europe (Poland). To date, the appearance of E.
cloacae producing carbapenemase from the OXA-48 family has
been reported in Turkey,1 Senegal,2 Morocco,3 France,4 Belgium,5
the UK,6 and Germany.7 The patient, who had no prior history of
hospital admission abroad, did not develop the infection caused by
the carbapenem-resistant E. cloacae until day 24 after surgery,
hence the primary source of the pathogens appears to be
nosocomial.
Furthermore, the microorganisms studied in our research
developed resistance to other ‘last-resort’ agents, namely colistin
and tigecycline. Interestingly, cases of tigecycline resistance have
been reported previously,4–6 while OXA-48-producing E. cloacae
resistant to colistin has not been described before. Pathogens
originating from bronchial secretions exhibited resistance to both
tigecycline and colistin.
Since the occurrence of bacteria resistant to virtually all
available antimicrobial agents is increasing constantly, it appears
that in the future we will have to manage untreatable infections,
similar to those occurring before the introduction of the ﬁrst
antimicrobial compound to therapy. Constant monitoring of the
local epidemiology could prevent potential outbreaks of infections
caused by multidrug-resistant bacteria. There is a crucial need forsurveillance programs aimed at screening for carbapenemase-
producing Gram-negative bacteria, especially in patients trans-
ferred from high-incidence areas.
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